{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:51:11Z","timestamp":1791337871397,"version":"4.3.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","award":["RS-2025-02223246"],"award-info":[{"award-number":["RS-2025-02223246"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurosci"],"DOI":"10.1186\/s12868-026-01026-1","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:35:15Z","timestamp":1783935315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leucettine L41 Ameliorates Tau pathology and neuroinflammation in Parkinson\u2019s disease models"],"prefix":"10.1186","volume":"27","author":[{"given":"Subin","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunha","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeyeon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunjoo","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwi-yeol","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Sook","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"1026_CR1","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.","journal-title":"Nat Rev Dis Primers"},{"key":"1026_CR2","doi-asserted-by":"publisher","first-page":"1150940","DOI":"10.3389\/fimmu.2023.1150940","volume":"14","author":"JH Park","year":"2023","unstructured":"Park JH, Hwang JW, Lee HJ, Jang GM, Jeong YJ, Cho J, Seo J, Hoe HS. Lomerizine inhibits LPS-mediated neuroinflammation and tau hyperphosphorylation by modulating NLRP3, DYRK1A, and GSK3\u03b1\/\u03b2. Front Immunol. 2023;14:1150940.","journal-title":"Front Immunol"},{"issue":"2","key":"1026_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s12035-012-8267-8","volume":"47","author":"CM Lema Tom\u00e9","year":"2013","unstructured":"Lema Tom\u00e9 CM, Tyson T, Rey NL, Grathwohl S, Britschgi M, Brundin P. Inflammation and \u03b1-synuclein\u2019s prion-like behavior in Parkinson\u2019s disease\u2013is there a link? Mol Neurobiol. 2013;47(2):561\u201374.","journal-title":"Mol Neurobiol"},{"issue":"4","key":"1026_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/jnen\/nlx007","volume":"76","author":"GG Kovacs","year":"2017","unstructured":"Kovacs GG, Robinson JL, Xie SX, Lee EB, Grossman M, Wolk DA, Irwin DJ, Weintraub D, Kim CF, Schuck T, et al. Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases. J Neuropathol Exp Neurol. 2017;76(4):270\u201388.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1026_CR5","doi-asserted-by":"crossref","unstructured":"Menon S, Armstrong S, Hamzeh A, Visanji NP, Sardi SP, Tandon A. Alpha-synuclein targeting therapeutics for Parkinson's disease and related synucleinopathies. Front Neurol. 2022;13.","DOI":"10.3389\/fneur.2022.852003"},{"issue":"1","key":"1026_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17(1):5\u201321.","journal-title":"Nat Rev Neurosci"},{"issue":"12","key":"1026_CR7","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1021\/jm200274d","volume":"54","author":"M Debdab","year":"2011","unstructured":"Debdab M, Carreaux F, Renault S, Soundararajan M, Fedorov O, Filippakopoulos P, Lozach O, Babault L, Tahtouh T, Baratte B, et al. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011;54(12):4172\u201386.","journal-title":"J Med Chem"},{"issue":"48","key":"1026_CR8","doi-asserted-by":"publisher","first-page":"34850","DOI":"10.1074\/jbc.M707358200","volume":"282","author":"SR Ryoo","year":"2007","unstructured":"Ryoo SR, Jeong HK, Radnaabazar C, Yoo JJ, Cho HJ, Lee HW, Kim IS, Cheon YH, Ahn YS, Chung SH, et al. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J Biol Chem. 2007;282(48):34850\u20137.","journal-title":"J Biol Chem"},{"issue":"44","key":"1026_CR9","doi-asserted-by":"publisher","first-page":"33250","DOI":"10.1074\/jbc.M606147200","volume":"281","author":"EJ Kim","year":"2006","unstructured":"Kim EJ, Sung JY, Lee HJ, Rhim H, Hasegawa M, Iwatsubo T, Min do S, Kim J, Paik SR, Chung KC. Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. J Biol Chem. 2006;281(44):33250\u20137.","journal-title":"J Biol Chem"},{"key":"1026_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.freeradbiomed.2020.08.030","volume":"160","author":"H-j Lee","year":"2020","unstructured":"Lee H-j, Woo H, Lee H-E, Jeon H, Ryu K-Y, Nam Jh, Jeon SG, Park H, Lee J-S, Han K-M, et al. The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation. Free Radic Biol Med. 2020;160:575\u201395.","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"1026_CR11","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1007\/s10753-022-01699-w","volume":"45","author":"C Ju","year":"2022","unstructured":"Ju C, Wang Y, Zang C, Liu H, Yuan F, Ning J, Shang M, Ma J, Li G, Yang Y, et al. Inhibition of Dyrk1A Attenuates LPS-Induced Neuroinflammation via the TLR4\/NF-\u03baB P65 Signaling Pathway. Inflammation. 2022;45(6):2375\u201387.","journal-title":"Inflammation"},{"issue":"11","key":"1026_CR12","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.euroneuro.2015.03.018","volume":"25","author":"G Naert","year":"2015","unstructured":"Naert G, Ferr\u00e9 V, Meunier J, Keller E, Malmstr\u00f6m S, Givalois L, Carreaux F, Bazureau JP, Maurice T. Leucettine L41, a DYRK1A-preferential DYRKs\/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric A\u03b225\u201335 peptide administration in mice. Eur Neuropsychopharmacol. 2015;25(11):2170\u201382.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"1026_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.4155\/fmc-2016-0013","volume":"8","author":"S Stotani","year":"2016","unstructured":"Stotani S, Giordanetto F, Medda F. DYRK1A inhibition as potential treatment for Alzheimer\u2019s disease. Future Med Chem. 2016;8(6):681\u201396.","journal-title":"Future Med Chem"},{"issue":"5","key":"1026_CR14","doi-asserted-by":"publisher","first-page":"e13000","DOI":"10.1111\/acel.13000","volume":"18","author":"B Melchior","year":"2019","unstructured":"Melchior B, Mittapalli GK, Lai C, Duong-Polk K, Stewart J, G\u00fcner B, Hofilena B, Tjitro A, Anderson SD, Herman DS, et al. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer\u2019s disease. Aging Cell. 2019;18(5):e13000.","journal-title":"Aging Cell"},{"issue":"2","key":"1026_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.38212\/2224-6614.3462","volume":"31","author":"HJ Tu","year":"2023","unstructured":"Tu HJ, Su CJ, Peng CS, Lin TE, HuangFu WC, Hsu KC, Hwang TL, Pan SL. Urolithin A exhibits a neuroprotective effect against Alzheimer\u2019s disease by inhibiting DYRK1A activity. J Food Drug Anal. 2023;31(2):358\u201370.","journal-title":"J Food Drug Anal"},{"key":"1026_CR16","doi-asserted-by":"crossref","unstructured":"Demuro S, Di Martino RMC, Ortega JA, Cavalli A. GSK-3\u03b2, FYN, and DYRK1A: master regulators in neurodegenerative pathways. Int J Mol Sci. 2021;22(16).","DOI":"10.3390\/ijms22169098"},{"issue":"1","key":"1026_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0006-8993(03)03172-X","volume":"985","author":"H Cardenas","year":"2003","unstructured":"Cardenas H, Bolin LM. Compromised reactive microgliosis in MPTP-lesioned IL-6 KO mice. Brain Res. 2003;985(1):89\u201397.","journal-title":"Brain Res"},{"issue":"8","key":"1026_CR18","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrd.2018.97","volume":"17","author":"MSJ Mangan","year":"2018","unstructured":"Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discovery. 2018;17(8):588\u2013606.","journal-title":"Nat Rev Drug Discovery"}],"container-title":["BMC Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12868-026-01026-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12868-026-01026-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12868-026-01026-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:15:42Z","timestamp":1791335742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12868-026-01026-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1026"],"URL":"https:\/\/doi.org\/10.1186\/s12868-026-01026-1","relation":{},"ISSN":["1471-2202"],"issn-type":[{"value":"1471-2202","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All applicable national and institutional guidelines for the care and use of animals were followed. The protocols for animal experiments were approved by the Animal Ethics Committee of Naason Science, Inc with the code number of KBIO-IACUC-2023-053.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"42"}}